Susceptibility of phytoplankton to the increasing presence of active pharmaceutical ingredients (APIs) in the aquatic environment: A review.

Human and veterinary pharmaceuticals either in the form of un-metabolized, incompletely metabolized, and metabolized drugs are increasingly present in aquatic ecosystems. These active pharmaceutical ingredients from pharmaceutical industries, hospitals, agricultural, and domestic discharges find their way into water systems - where they adversely affect non-target organisms like phytoplankton. Different aspects of phytoplankton life; ranging from growth, reproduction, morphology, physiology, biochemical composition, oxidative response, proteomics, and transcriptomics are altered by pharmaceuticals. This review discusses the currently available information on the susceptibility of phytoplankton to the ever-increasing presence of pharmaceutical products in the aquatic environment by focusing on the effect of APIs on the physiology, metabolome, and proteome profiles of phytoplankton. We also highlight gaps in literature concerning the salient underlining biochemical interactions between phytoplankton communities and pharmaceuticals that require an in-depth investigation. This is all in a bid to understand the imminent dangers of the contamination of water bodies with pharmaceutical products and how this process unfavorably affects aquatic food webs.

Effects of the antimalarial lumefantrine on Lemna minor, Raphidocelis subcapitata and Chlorella vulgaris.

Lumefantrine is used to treat uncomplicated malaria caused by pure or mixed Plasmodium falciparum infections and as a prophylactic against recrudescence following artemether therapy. However, the pharmaceutical is released into the aquatic environment from industrial effluents, hospital discharges, and human excretion. This study assessed the effects of lumefantrine on the growth and physiological responses of the microalgae Chlorella vulgaris and Raphidocelis subcapitata (formerly known as Selenastrum capricornutum and Pseudokirchneriella subcapitata) and the aquatic macrophyte Lemna minor. The microalgae and macrophyte were exposed to 200-10000 µg l-1 and 16-10000 µg l-1 lumefantrine, respectively. Lumefantrine had a variable effect on the growth of the aquatic plants investigated. There was a decline in the growth of R. subcapitata and L. minor post-exposure to the drug. Contrarily, there was stimulation in the growth of Chlorella vulgaris. All experimental plants had a significant increase in lipid peroxidation, which was accompanied by an increase in malondialdehyde content. Peroxidase activity of L. minor increased only at low lumefantrine concentrations, while the opposite occurred at higher levels of the drug. Incubation in lumefantrine contaminated medium significantly up-regulated the activity of R. subcapitata cultures. Glutathione S-transferase of L. minor exposed to lumefantrine treatments had substantially higher activities than the controls. Our findings suggest lumefantrine could have adverse but variable effects on the growth and physiology of the studied aquatic plants.